Page last updated: 2024-11-13

imm-h004

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IMM-H004: Neuroprotective Agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	72375487
CHEMBL ID	2419402
MeSH ID	M0594268

Synonyms (7)

Synonym
CHEMBL2419402
imm-h004
AKOS025396059
1456807-80-9
7-hydroxy-5-methoxy-4-methyl-3-(4-methylpiperazin-1-yl)-2h-chromen-2-one
2h-1-benzopyran-2-one, 7-hydroxy-5-methoxy-4-methyl-3-(4-methyl-1-piperazinyl)-
7-hydroxy-5-methoxy-4-methyl-3-(4-methyl piperazin-1-yl)-coumarin

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" The results of this study lend further credence to the notion that IMM-H004 is a 'multipotent therapeutic agrent' that reduces toxic levels of brain Aβ, and holds the potential to protect neuronal mitochondrial function in Alzheimer's disease."	( IMM-H004, a novel coumarin derivative compound, protects against amyloid beta-induced neurotoxicity through a mitochondrial-dependent pathway. Chen, NH; Han, N; Hu, JF; Ji, HJ; Li, ZP; Liu, G; Song, XY; Sun, MN; Wu, DH; Yuan, YH; Zhu, ZX, 2013)	2.07

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay ID	Title	Year	Journal	Article
AID768364	Cmax in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv measured at 2 mins by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768378	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of brain-water content at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768379	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size at 6 mg/kg, iv measured 24 hrs post reperfusion by TTC staining assay relative to vehicle-treated control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768374	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by TUNEL assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768376	In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in hippocampus measured 24 hrs post reperfusion by nissl staining assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768371	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as upregulation of Bcl-2 protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to v	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768380	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size at 3 mg/kg, iv measured 24 hrs post reperfusion by TTC staining assay relative to vehicle-treated control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768357	Volume of distribution in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768361	Terminal half life in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768352	Drug uptake in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv measured at 60 mins by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768353	Drug uptake in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv measured at 60 mins by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768359	AUC in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768363	Tmax in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768375	In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in cerebral cortex measured 24 hrs post reperfusion by nissl staining assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768358	AUC in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768373	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuronal loss in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by TUNEL assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768355	Clearance in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768360	Terminal half life in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768362	Tmax in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768383	Cytotoxicity against rat PC12 cells assessed as cell proliferation at 10 uM by MTT assay relative to control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768354	Clearance in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768381	In vivo neuroprotective activity in iv dosed Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as reduction of infarct size measured 24 hrs post reperfusion by TTC staining assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768365	Cmax in Sprague-Dawley rat plasma at 2 x 10'-5 mol/kg, iv measured at 2 mins by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768369	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of Bax protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to vehic	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768366	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of cleaved caspase-3 protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768356	Volume of distribution in Sprague-Dawley rat cortex at 2 x 10'-5 mol/kg, iv by LC-MS analysis	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768372	In vivo neuroprotective activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as suppression of neuropathological changes at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by uranyl acetate/lead citrate staining-bas	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768382	Neuroprotective activity in rat PC12 cells assessed as attenuation of oxygen-glucose deprivation-induced cellular damage at 10 uM by MTT assay relative to control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768368	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of Bax protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative to v	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768367	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as inhibition of cleaved caspase-3 protein expression in hippocampus at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis rel	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
AID768370	Anti-ischemia activity in Sprague-Dawley rat transient middle cerebral artery occlusion model assessed as upregulation of Bcl-2 protein expression in cerebral cortex at 1.5 to 6 mg/kg, iv measured 24 hrs post reperfusion by Western blot analysis relative	2013	European journal of medicinal chemistry, Sep, Volume: 67	Coumarin derivatives protect against ischemic brain injury in rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	15 (100.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.74 (24.57)
Research Supply Index	2.77 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.11	1	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
edaravone [no description available]	2.5	2	pyrazolone	antioxidant; radical scavenger
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.08	1
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	4.15	14	benzenes; hydroxycoumarin; methyl ketone
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	2.57	2	ketal

Condition	Relationship Strength	Studies
Cerebral Ischemia [description not available]	3.23	5
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	3.23	5
Acute Confusional Senile Dementia [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.05	4
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.21	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.52	2
Brain Swelling [description not available]	2.15	1
Injury, Ischemia-Reperfusion [description not available]	2.86	3
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.15	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	7.86	3
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.52	2
Apoplexy [description not available]	2.21	1
Acute Brain Injuries [description not available]	2.61	2
Innate Inflammatory Response [description not available]	2.54	2
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.21	1
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.61	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.54	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.21	1
Brain Hemorrhage, Cerebral [description not available]	2.1	1
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	2.1	1
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	2.1	1
Academic Disorder, Developmental [description not available]	2.11	1
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2.11	1
Anterior Circulation Transient Ischemic Attack [description not available]	2.15	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.15	1
Age-Related Memory Disorders [description not available]	2.13	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.13	1

chemdatabank.com